It is recommended that MATULANE be given only by or under the supervision of a physician experienced in the use of potent antineoplastic drugs. Adequate clinical and laboratory facilities should be available to patients for proper monitoring of treatment.
Matulane (procarbazine hydrochloride), a hydrazine derivative antineoplastic agent, is available as capsules containing the equivalent of 50 mg procarbazine as the hydrochloride.
Matulane is indicated for use in combination with other anticancer drugs for the treatment of Stage III and IV Hodgkin's disease. Matulane is used as part of the MOPP (nitrogen mustard, vincristine, procarbazine, prednisone) regimen.
Published Studies Related to Matulane (Procarbazine)
Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. [2010.10.20]
PURPOSE: Temozolomide (TMZ) is an alkylating agent licensed for treatment of high-grade glioma (HGG). No prospective comparison with nitrosourea-based chemotherapy exists. We report, to our knowledge, the first randomized trial of procarbazine, lomustine, and vincristine (PCV) versus TMZ in chemotherapy-naive patients with recurrent HGG... CONCLUSION: Although TMZ (both arms combined) did not show a clear benefit compared with PCV, comparison of the TMZ schedules demonstrated that the 21-day schedule was inferior to the 5-day schedule in this setting. This challenges the current understanding of increasing TMZ dose-intensity by prolonged scheduling.
Comparative study of two mechlorethamine, vincristine, procarbazine, and prednisone derived chemotherapeutic protocols for the management of pediatric Hodgkin lymphoma (HL): single-center 5-year experience. [2010.04]
We aimed for the comparison of two protocols (OAP and COMP) as chemotherapy treatment in children with Hodgkin lymphoma (HL). A total of 119 children newly diagnosed with HD were divided to receive either the anthracycline-based OAP protocol or the alkylating-agent-based COMP protocol... Patients treated with the COMP protocol achieved a better response and less toxicity but with similar survival to those given the OAP protocol.
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. [2009.12.10]
PURPOSE: The standard of care for anaplastic gliomas is surgery followed by radiotherapy. The NOA-04 phase III trial compared efficacy and safety of radiotherapy followed by chemotherapy at progression with the reverse sequence in patients with newly diagnosed anaplastic gliomas... CONCLUSION: Initial radiotherapy or chemotherapy achieved comparable results in patients with anaplastic gliomas. IDH1 mutations are a novel positive prognostic factor in anaplastic gliomas, with a favorable impact stronger than that of 1p/19q codeletion or MGMT promoter methylation.
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. [2006.06.20]
PURPOSE: Anaplastic oligodendrogliomas are more responsive to chemotherapy than high-grade astrocytomas. We investigated, in a multicenter randomized controlled trial, whether adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy improves overall survival (OS) in newly diagnosed patients with anaplastic oligodendrogliomas or anaplastic oligoastrocytomas... CONCLUSION: Adjuvant PCV chemotherapy does not prolong OS but does increase PFS in anaplastic oligodendroglioma. Combined loss of 1p/19q identifies a favorable subgroup of oligodendroglial tumors. No genetic subgroup could be identified that benefited with respect to OS from adjuvant PCV.
Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi. [2006.03]
Patients with aggressive NHL who fail initial treatment or subsequently relapse have a very poor outcome and less than 20-25% achieve a prolonged disease-free interval with salvage therapies. To improve the outcome of patients with refractory aggressive NHL not suitable for High Dose Therapy (HDT) and Autologous Stem Cell Transplant (ASCT), the efficacy of a combination of gemcitabine, vinorelbine, procarbazine and prednisone (ViGePP) were tested.
Clinical Trials Related to Matulane (Procarbazine)
Procarbazine and Lomustine in Recurrent Glioblastoma [Recruiting]
The combination therapy of temozolomide and radiation has been established as the standard
therapy for the initial treatment of glioblastoma. However, the prognosis for patients with
recurrent/ refractory glioblastoma is dismal, with a median survival of 3~6 months. There is
no efficient and standard care at the time of recurrence or progression following
temozolomide administration. Recently, many clinicians have reassessed the efficacy of
second-line chemotherapeutic agents such as nitrosoureas for the treatment of
recurrent/refractory glioblastoma. It is very important that the effect of the agent is
sustained and the adverse effect is reduced to preserve the quality of life in recurrent
settings. We have realized that the clinical features of Korean patients are very different
from those of foreign patients. Therefore, it is mandatory to develop the new strategy for
the treatment of Korean patients. We modify the PCV chemotherapy in the dose and
administration schedule of CCNU and procarbazine to reduce the side effect, especially
hematologic problems. The dose of CCNU is reduced to 75mg/m2 and the interval between CCNU
and procarbazine is increased. Moreover, vincristine is excluded because BBB permeability of
vincristine is very poor and the risk of neurotoxicity is high. We introduce the modified PC
chemotherapy regimen for the treatment of recurrent/refractory glioblastoma, which is the
first multicenter trial for glioblastoma patients in Korea.
Methotrexate and Temozolomide Versus Methotrexate, Procarbazine, Vincristine and Cytarabine [Recruiting]
The purpose of this study is to evaluate two types of chemotherapy for primary central
nervous system lymphoma in the elderly (age older than 60) :
- Methotrexate, procarbazine, vincristine and cytarabine
- Methotrexate and temozolomide
Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas [Active, not recruiting]
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Combining more than one drug may kill more tumor cells. It is not
yet known whether giving procarbazine alone or with isotretinoin is more effective for
recurrent primary malignant glioma.
PURPOSE: Randomized phase III trial to compare the effectiveness of procarbazine alone or
with isotretinoin in treating patients with recurrent primary malignant gliomas.
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma [Recruiting]
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different
ways. Some find cancer cells and help kill them or carry cancer-killing substances to them.
Others interfere with the ability of cancer cells to grow and spread. Drugs used in
chemotherapy, such as methotrexate, vincristine sulfate, procarbazine hydrochloride, and
cytarabine, work in different ways to stop the growth of cancer cells, either by killing the
cells or by stopping them from dividing. Radiation therapy uses high energy x rays to kill
cancer cells. It is not yet know whether rituximab and combination chemotherapy are more
effective when given with or without radiation therapy in treating patients with primary
central nervous system lymphoma.
PURPOSE: This randomized phase II trial studies how well giving rituximab and combination
chemotherapy with or without radiation therapy works in treating patients with primary
central nervous system lymphoma.
Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma [Recruiting]
The purpose of this study is to determine the safety of this new treatment offered in this
study. PCNSL can be cured in less than half of patients with standard treatment, a
combination of chemotherapy and brain radiation. Also, the combination of chemotherapy and
brain radiation may result in serious lasting side effects. Most patients older than age 60
develop memory problems, difficulty walking or inability to control their bladder. Some
patients younger than age 60 also develop these side effects.
Reports of Suspected Matulane (Procarbazine) Side Effects
Febrile Neutropenia (5),
Atrial Fibrillation (5),
Pleural Effusion (4), more >>
Page last updated: 2011-12-09